Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study

Donald W Black; Stephan Arndt; William H Coryell; Tami Argo; Kelsie T Forbush; Martha C Shaw; Paul Perry; Jeff Allen

doi:10.1097/01.jcp.0000264985.25109.25

Back

Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study

Journal article

Peer reviewed

Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study

Donald W Black, Stephan Arndt, William H Coryell, Tami Argo, Kelsie T Forbush, Martha C Shaw, Paul Perry and Jeff Allen

Journal of clinical psychopharmacology, Vol.27(2), pp.143-150

04/2007

DOI: 10.1097/01.jcp.0000264985.25109.25

PMID: 17414236

View Online

Abstract

We tested the efficacy of bupropion in the treatment of persons with pathological gambling (PG). Nondepressed, healthy subjects with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition PG were randomly assigned to placebo or flexibly dosed bupropion in a 12-week double-blind trial. Outcome measures included the Yale-Brown Obsessive-Compulsive Scale modified for PG, the Gambling Severity Assessment Scale, the Clinical Global Impression Improvement and Severity Scales, the Global Assessment Scale, the Timeline Follow Back, the Attention-Deficit/Hyperactivity Disorder Rating Scale, and the Sheehan Disability Scale. Thirty-nine subjects (28 men, 11 women) were randomized to bupropion (n = 18) or placebo (n = 21). The 2 groups were similar on demographic and clinical measures. There were few differences between the treatment groups on any primary or secondary outcome measure, although subjects in each cell experienced significant improvement. Of subjects with at least 1 postrandomization visit, 35.7% of bupropion and 47.1% of placebo recipients experienced "much" or "very much" improvement on the Clinical Global Impression Improvement Scale. The trial was complicated by a high noncompletion rate (43.6%). Bupropion was well tolerated. Bupropion and placebo recipients did equally well in a short-term trial, with improvement seen as early as the first week of treatment. The high placebo response rate and the high noncompletion rate each reflect the challenge inherent in treating persons with PG.

Antidepressive Agents, Second-Generation - adverse effects

Patient Dropouts - statistics & numerical data

Diagnostic and Statistical Manual of Mental Disorders

Double-Blind Method

Gambling - psychology

Humans

Middle Aged

Male

Treatment Outcome

Antidepressive Agents, Second-Generation - therapeutic use

Dose-Response Relationship, Drug

Obsessive-Compulsive Disorder - psychology

Obsessive-Compulsive Disorder - drug therapy

Adult

Female

Anxiety - chemically induced

Bupropion - adverse effects

Headache - chemically induced

Xerostomia - chemically induced

Bupropion - therapeutic use

Details

Title: Subtitle: Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study
Creators: Donald W Black - Department of Psychiatry, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA 52242, USA. donald-black@uiowa.edu
Stephan Arndt
William H Coryell
Tami Argo
Kelsie T Forbush
Martha C Shaw
Paul Perry
Jeff Allen
Resource Type: Journal article
Publication Details: Journal of clinical psychopharmacology, Vol.27(2), pp.143-150
DOI: 10.1097/01.jcp.0000264985.25109.25
PMID: 17414236
NLM abbreviation: J Clin Psychopharmacol
ISSN: 0271-0749
eISSN: 1533-712X
Publisher: United States
Grant note: R21 MH-063289 / NIMH NIH HHS
Language: English
Date published: 04/2007
Academic Unit: Pharmacy; Psychiatry; Biostatistics; Nursing; Injury Prevention Research Center
Record Identifier: 9984003991902771

Metrics

59 Record Views

57 Times Cited - Web of Science